Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe
about
Influence of infection during pregnancy on fetal developmentThe PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral DrugsIs protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysisSurveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.Getting to 90-90-90 in paediatric HIV: What is needed?Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.Pregnant women's access to PMTCT and ART services in South Africa and implications for universal antiretroviral treatment.Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countriesHighly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trialPregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conceptionVaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocolPredictors of adverse pregnancy outcomes in women infected with HIV in Latin America and the Caribbean: a cohort study.Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.Mitochondrial toxicity in human pregnancy: an update on clinical and experimental approaches in the last 10 years.Antiretroviral regimens in pregnancy and breast-feeding in Botswana.Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe.Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational studyRisk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008Preterm Birth and Low Birth Weight after In Utero Exposure to Antiretrovirals Initiated during Pregnancy in Yaoundé, CameroonMaternal HIV infection associated with small-for-gestational age infants but not preterm births: evidence from rural South Africa.Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe.Incident pregnancy and pregnancy outcomes among HIV-infected women in Uganda and ZimbabweThe physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenCombination antiretroviral use and preterm birth.Duration of cART Before Delivery and Low Infant Birthweight Among HIV-Infected Women in Lusaka, Zambia.Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy.Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Routine antenatal HIV testing: the responses and perceptions of pregnant women and the viability of informed consent. A qualitative study
P2860
Q24276210-F41C861C-9B64-465E-AB8D-EE95E07E47D7Q26744617-117A070D-D07D-43FD-A979-B42CB4AE0EAAQ28066290-BF955082-60A8-42EA-B332-1CAE8640E411Q30244368-C8F5522F-B4C4-4761-90E2-7DA105EC171FQ30385352-25BF282C-3994-4BF0-93D7-1B4BF95BDE83Q30987069-EC193841-BCAC-41E1-A90B-66D376458202Q31043326-5278DCE6-A7DB-4E14-950E-73ABF722A3B6Q33294899-260B22BF-AEE4-429E-B42A-ECE140EA60CDQ33705707-6E38CB53-7598-4353-8C64-12F1BC96BC90Q33715492-9506BAF6-5EF3-4885-8954-C274A5FE7C3FQ33811136-61911599-F43F-4920-9E93-03CD44E706D8Q33830084-A0278847-636A-4210-82D1-E334849DBBC5Q33916922-BF57B877-DA3B-40D3-940D-92BF040700D5Q34146634-7973B2E4-2C18-4173-BCFE-1E9907657D9DQ34158407-88F954A1-4C70-4E32-B17D-9B8AB283640BQ34306176-0EF8D926-3189-44AC-8172-D453BE5D99C5Q34348392-F9B476AE-53CB-4F62-BCBC-7EB84ED484ADQ34395082-6C135FA0-870F-4E31-A9FD-396E04C32EEDQ34615517-30102B11-0C3E-4DF9-A14A-BECCBB3BBCF4Q35037981-EDBB02FC-EF24-43A3-8E8A-4643D1A9270FQ35184921-0AC50C72-D891-4A38-ACB6-38E37DD96B19Q35551457-C7789E60-0252-40B7-B51D-BA9214820D88Q35557216-91DB692F-3DA0-45F9-AC6D-02054D0CBA02Q35689226-EC62961B-DC93-4AAD-BC73-8E1E9B3FB51BQ35691443-45A1AF58-3850-49AB-AB9E-8ED74A6132B0Q35738557-63804B66-2F44-4567-837D-6CCBB06A3605Q35738687-9A1E147A-7CCD-4F71-917E-1E3D7F11F317Q35960319-85A49991-6626-409A-B03A-B8C656F0189FQ35964999-B7ED1614-BFA1-4F1D-83CF-AC64148451A4Q35976283-D9E1577A-C64C-4F2C-940B-1E5EE51BF1F7Q36072127-6582763C-4130-4AB3-ABB1-0D256FDE4115Q36193260-C0A425DB-765E-4AFE-A974-2FCE347DCE4AQ36322625-4B4F1FB3-4AF2-445F-B921-5F9656AFF505Q36349683-CCA0D20D-8BDB-4510-ABA4-CDBBE5AB4FD0Q36547343-C4FE399C-B281-4C67-9270-0EA1DDBCDD09Q36678190-17ED0CE7-D16B-485E-8EA5-A80B32A2F74DQ36711601-5018B392-2F30-43B0-BC57-899A3FC9C609Q36816616-45BF9B8C-24E7-4581-9989-43F333E9BAEBQ36851168-4AA36013-EB68-4ED4-8BDB-8F9A3D39FE70Q37005259-C65F7A41-439C-409D-94FE-C6755476F9F0
P2860
Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe
description
im November 2004 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована в листопаді 2004
@uk
name
Increased risk of adverse preg ...... tiretroviral therapy in Europe
@en
type
label
Increased risk of adverse preg ...... tiretroviral therapy in Europe
@en
prefLabel
Increased risk of adverse preg ...... tiretroviral therapy in Europe
@en
P1433
P1476
Increased risk of adverse preg ...... tiretroviral therapy in Europe
@en
P2093
Deven Patel
P304
P407
P577
2004-11-19T00:00:00Z